Wellbiotec Co., Ltd.

KOSE:A010600 Stock Report

Market Cap: ₩1.0b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Wellbiotec Past Earnings Performance

Past criteria checks 0/6

Wellbiotec has been growing earnings at an average annual rate of 3.3%, while the Luxury industry saw earnings growing at 14.7% annually. Revenues have been declining at an average rate of 5.2% per year.

Key information

3.35%

Earnings growth rate

20.53%

EPS growth rate

Luxury Industry Growth21.63%
Revenue growth rate-5.19%
Return on equity-85.47%
Net Margin-16.42%
Last Earnings Update30 Sep 2025

Recent past performance updates

Recent updates

Analysis Article • Mar 22

Take Care Before Jumping Onto Wellbiotec Co., Ltd. (KRX:010600) Even Though It's 28% Cheaper

To the annoyance of some shareholders, Wellbiotec Co., Ltd. ( KRX:010600 ) shares are down a considerable 28% in the...
Analysis Article • Dec 11

Here's Why Wellbiotec (KRX:010600) Can Afford Some Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Revenue & Expenses Breakdown

How Wellbiotec makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSE:A010600 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2579,765-13,09512,7620
30 Jun 2582,879-16,60812,8060
31 Mar 2587,282-17,94712,2630
31 Dec 2483,301-19,06214,0760
30 Sep 2446,620-68,65216,6610
30 Jun 2448,773-65,52519,0000
31 Mar 2450,873-60,26021,4970
31 Dec 2359,746-59,08220,9560
30 Sep 2374,680-22,52518,4320
30 Jun 2396,222-23,29618,2880
31 Mar 23122,501-25,08618,8080
31 Dec 22158,116-20,88119,7610
30 Sep 22157,959-25,95313,27597
30 Jun 22164,626-23,42213,939147
31 Mar 22153,331-29,09912,986186
31 Dec 21108,377-34,86111,937186
30 Sep 21107,138-24,7279,16189
30 Jun 2175,149-31,38013,26664
31 Mar 2159,256-50,76915,21128
31 Dec 2060,431-50,51317,52342
30 Sep 2058,699-34,16323,88761
30 Jun 2057,809-28,58218,88439
31 Mar 2053,086-7,91716,52836
31 Dec 1952,333-4,33314,04322
30 Sep 1974,363-9,32115,291-13
30 Jun 1974,922-11,34513,971-3
31 Mar 1974,007-11,43612,979-1
31 Dec 1873,932-13,75412,0980
30 Sep 1875,574-15,46610,40116
30 Jun 1871,854-12,0329,1243
31 Mar 1872,043-8,0188,3221
31 Dec 1770,786-8,7427,7760
30 Sep 1773,822-2,9447,8460
30 Jun 1779,188-4,7978,0370
31 Mar 1780,912-4,5028,1130
31 Dec 1685,292-2,4508,2520
30 Sep 1693,394-2,1638,1880
30 Jun 1698,733-1358,2170
31 Mar 16105,3367668,4650
31 Dec 15112,4885508,4640
30 Sep 15115,378-5,5779,3340
30 Jun 15116,840-5,5799,4430
31 Mar 15115,684-7,6979,2580

Quality Earnings: A010600 is currently unprofitable.

Growing Profit Margin: A010600 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A010600 is unprofitable, but has reduced losses over the past 5 years at a rate of 3.3% per year.

Accelerating Growth: Unable to compare A010600's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A010600 is unprofitable, making it difficult to compare its past year earnings growth to the Luxury industry (-10.1%).

Return on Equity

High ROE: A010600 has a negative Return on Equity (-85.47%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/27 00:58
End of Day Share Price 2026/01/23 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Wellbiotec Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.